ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

Abbott Fills Out Leadership Team for Pharma Spinoff AbbVie

By Peter Loftus Abbott Laboratories (ABT) on Monday unveiled the leadership team for the proprietary pharmaceutical division that it plans to separate into an independent company. Abbott had previously disclosed that Richard A. Gonzalez, the 57-year-old leader of Abbott's pharmaceutical business, will serve as chairman and chief executive of the new company, AbbVie, which Abbott plans to establish via a tax-free distribution of AbbVie shares to Abbott shareholders by the end of this year. Abbott Labs disclosed in a filing Monday with the U.S. Securities and Exchange Commission that it is tapping other in-house executives to go with Mr. Gonzalez to lead AbbVie. They include William J. Chase, 44, who will serve as AbbVie's chief financial officer; he is currently vice president of licensing and acquisitions at Abbott Laboratories. Abbott Laboratories' general counsel, Laura J. Schumacher, 48, will take the same position at AbbVie. AbbVie will name John M. Leonard as senior vice president of pharmaceutical research and development. Dr. Leonard currently holds the same position at Abbott. Also, AbbVie will name Carlos Alban as senior vice president of proprietary pharmaceutical products, global commercial operations, the same position he holds at Abbott Labs. Timothy J. Richmond, currently divisional vice president of compensation and benefits at Abbott Labs, will serve as chief human resources officer at AbbVie. Abbott also disclosed compensation for some of the top officers of AbbVie. Mr. Gonzalez's total compensation for 2011 was valued at $5.6 million, down from $7.6 million for 2010. This included base salary of $825,000, plus stock and option awards and other compensation. Ms. Schumacher's compensation was valued at $5.6 million, down from $7.1 million. Other total compensation for 2011: Mr. Chase, $1.8 million; Mr. Alban, $3.9 million; and Dr. Leonard, $3.5 million. Miles White will remain CEO of Abbott Labs, which will retain the rest of its businesses, including nutrition, diagnostic and medical-device products. Abbott shares fell 0.5% to $60.20 on Monday. Write to Peter Loftus at

Stock News for Abbott Labs (ABT)
07/20/201615:36:00Abbott Results, Helped by Product Launches, Top Views
07/20/201611:10:00St. Jude Medical Logs Double-Digit Sales Growth -- Update
07/20/201609:20:00Abbott Labs Profit Tops Views
07/20/201609:03:00Abbott Labs Profit Tops Views
07/20/201608:30:00St. Jude Medical Logs Double-Digit Sales Growth
07/20/201608:25:00St. Jude Medical Logs Double-Digit Sales Growth
07/20/201607:52:30Current Report Filing (8-k)
07/20/201607:45:00Abbott Reports Second-Quarter 2016 Results
07/15/201612:49:00FDA Approves the Tecnis Symfony® Intraocular Lenses, the First...
07/14/201619:00:00Alere Expects to Restate Financial Results
07/14/201613:15:00Health Canada approves Abbott's Absorb™ bioresorbable stent, t...
07/13/201609:36:00U.S. Hot Stocks: Hot Stocks to Watch
07/12/201618:37:00FTC Requests Additional Info Before Approving Abbott Labs, St...
07/12/201616:33:46Current Report Filing (8-k)
07/11/201623:10:00Alere to Voluntarily Pull Blood-Monitoring Devices
07/11/201619:04:00Alere to Voluntarily Pull Blood-Monitoring Devices
07/06/201617:08:21Statement of Changes in Beneficial Ownership (4)
07/06/201617:07:54Statement of Changes in Beneficial Ownership (4)
07/06/201617:07:03Statement of Changes in Beneficial Ownership (4)
07/05/201623:53:00What's News: Business & Finance

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations